Logo

Takeda’s Vonvendi Receives the US FDA’s Approval for the Treatment of Severe Type 3 Von Willebrand Disease

Share this

Takeda’s Vonvendi Receives the US FDA’s Approval for the Treatment of Severe Type 3 Von Willebrand Disease

Shots:

  • The approval was based on the open-label, international multicenter study to evaluate the efficacy and safety of Vonvendi in 10 adult patients with severe Type 3 VWD who have received on-demand therapy
  • The results showed a 54.7% reduction in median annualized bleeding rates (ABR) for all bleeds (treated/untreated spontaneous and traumatic bleeding events)
  • Vonvendi is the 1st FDA approved recombinant VWF replacement therapy which is designed to reduce the frequency of bleeding episodes for severe Type 3 VWD for routine prophylactic use in adults who received on-demand therapy along with perioperative bleed management to treat VWD

Ref: Businesswire | Image:Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions